Novo Nordisk | NVO - Sales Revenues

Stock Price
36.95
Daily Change
0.51 1.40%
Monthly
0.76%
Yearly
-44.90%
Q2 Forecast
34.18

Novo Nordisk reported DKK12.53B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
ANI Pharmaceuticals USD 247.06M 19.25M Dec/2025
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Bausch Health Companies USD 2.8B 120M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Canopy Growth CAD 74.54M 7.86M Dec/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Drreddys Laboratories INR 87.27B 1.82B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Merck USD 16.4B 880M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Novo Nordisk DKK 79.14B 4.16B Dec/2025
Novo Nordisk DKK 12.53B 560M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Perrigo USD 1.11B 70M Dec/2025
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 283.44M 9.34M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
Zoetis USD 2.4B 0 Dec/2025